Esté José A
Institut de la Recerca de la Sida Caixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Spain.
IDrugs. 2002 May;5(5):385-7.
The 15th International Conference on Antiviral Research, organized by the International Society for Antiviral Research (ISAR), was held in Prague. Around 320 participants attended the meeting. In over 160 presentations, the latest preclinical and early clinical data on the development of new antiviral agents were presented. A satellite symposium entitled 'Clinical update on antiviral drugs' preceded the main meeting program. The conference was jointly chaired by Antonin Holy (Institute of Organic Chemistry and Biochemistry, Czech Republic) as the local representative and Earl Kern (University of Alabama at Birmingham, USA) of the ISAR Conference Committee. New agents that target distinct steps of the HIV life cycle were presented. Notably, novel HIV entry inhibitors acting on a post-binding step, a series of N-aminoimidazole derivatives blocking reverse transcriptase or post integrase events, and innovative strategies aimed at avoiding HIV drug resistance to reverse transcriptase (RT) inhibitors were described at the meeting. In this report, oral and poster presentations dealing with anti-HIV and antiretroviral agents in the development pipeline are discussed.
由国际抗病毒研究学会(ISAR)组织的第15届国际抗病毒研究会议在布拉格举行。约320名参会者出席了此次会议。在160多场报告中,展示了新型抗病毒药物研发的最新临床前和早期临床数据。在主要会议议程之前,举办了一场名为“抗病毒药物临床进展”的卫星研讨会。会议由作为当地代表的安东尼宁·霍利(捷克共和国有机化学与生物化学研究所)和ISAR会议委员会的厄尔·克恩(美国阿拉巴马大学伯明翰分校)共同主持。会上展示了针对HIV生命周期不同阶段的新型药物。值得注意的是,会上介绍了作用于结合后阶段的新型HIV进入抑制剂、一系列阻断逆转录酶或整合后事件的N-氨基咪唑衍生物,以及旨在避免HIV对逆转录酶(RT)抑制剂产生耐药性的创新策略。在本报告中,将讨论处于研发阶段的抗HIV和抗逆转录病毒药物的口头报告和海报展示。